Title
Anticoagulant Residues in Non-Target Wildlife – Assessing Sublethal Exposure to Brodifacoum without Lethal Sampling

Permalink
https://escholarship.org/uc/item/2q1567z9

Journal
Proceedings of the Vertebrate Pest Conference, 24(24)

Authors
Fisher, Penny
Shlosberg, Alan
Brown, Leslie
et al.

Publication Date
2010
**Poster Presentation**

**Anticoagulant Residues in Non-Target Wildlife – Assessing Sublethal Exposure to Brodifacoum without Lethal Sampling**

**Penny Fisher**  
Landcare Research, Lincoln, New Zealand

**Alan Shlosberg**  
Kimron Veterinary Institute, Bet Dagan, Israel

**Leslie Brown and Geoff Wright**  
Landcare Research, Lincoln, New Zealand

**ABSTRACT:** Residues of brodifacoum and other second-generation anticoagulant rodenticides are reported worldwide in a range of non-target wildlife, especially predatory or scavenging birds and mammals. Determination of exposure to brodifacoum in such cases relies on analysis of liver tissue. This limits current monitoring efforts to either destructive sampling of live birds or mammals to obtain liver, but more commonly opportunistic post-mortem liver sampling from carcasses in suitable condition. Also, detection of brodifacoum in liver often cannot be confirmed as a contributor to mortality, and within a potential ‘sublethal’ concentration range the toxicological significance of its presence is uncertain. We sought to determine whether dried blood spot (DBS) sampling could form the basis of a non-lethal, minimally invasive method for determining sublethal exposure to brodifacoum in live birds. Validation of a method for detecting brodifacoum in DBS samples, and preliminary comparison of brodifacoum concentrations in DBS and plasma samples, are described.

**KEY WORDS:** anticoagulant, birds, blood sampling, brodifacoum, dried blood spot, laboratory testing, nontarget species, residues, rodenticides

**INTRODUCTION**

Anticoagulant rodenticides inhibit the synthesis of vitamin K-dependent blood clotting factors in the liver (e.g., Thijssen 1995) by binding to the active site of vitamin K epoxide reductase (VKER) (Gebauer 2007). When this inhibition occurs over a sufficient period, blood will fail to coagulate in response to injury. Typical signs of anticoagulant toxicity in mammals and birds are increased blood coagulation times, haemorrhage, and anemia, with death through haemorrhage generally occurring several days after a lethal exposure (Pelfrene 2001). Among a range of ‘second-generation’ anticoagulant rodenticides (SGAR), brodifacoum is used in many countries to manage commensal rodents that share habitat and food sources with humans, particularly Norway rats (*Rattus norvegicus*), black rats (*R. rattus*), and house mice (*Mus musculus*). Brodifacoum is also registered for field use in bait stations against rodents and brushtail possums (*Trichosurus vulpecula*) in New Zealand (Hoare and Hare 2006). Broad-scale aerial application of brodifacoum bait is also an important conservation tool, instrumental in successful eradication of invasive rodents from an increasing number offshore islands (Howald et al. 2007).

Monitoring reports residual brodifacoum and other SGAR in an increasing range of wildlife species, including predatory birds and mammals (Albert et al. 2009, Mineau et al. 2003, Shore et al. 2003, Stone and Okoniewski 2003) and omnivorous mammals (Dowding et al. 2010). Brodifacoum is one of the most toxic of the anticoagulants, and residual concentrations have been shown to persist for prolonged periods in the livers of live animals (Eason et al. 1996, Laas et al. 1985, Fisher et al. 2003), providing an obvious focus on liver tissue to determine exposure. However, this creates limitations as it is generally not acceptable to kill non-target wildlife considered at risk of exposure in order to sample liver. In turn, this means that current residue data from non-target wildlife are most often based on opportunistic sampling from carcasses (e.g., road kills), where degradation may preclude necropsy or liver sampling. Where field exposure to brodifacoum is confirmed by measurable liver concentrations, it is then uncertain how long ago or how often the exposure had occurred, and where liver concentrations are relatively low (less than 1 ppm), whether it was sufficient to have caused mortality. Thus, the current indication of the range of non-target wildlife exposed to brodifacoum is generally retrospective, in looking to confirm exposure and its possible contribution to mortality after the fact.

Sublethal exposure of wildlife to anticoagulants may be more widespread in the environment than currently thought, but this is not practicable to investigate using liver tissue. A reliable, non-lethal and minimally invasive sampling procedure to determine exposure in live animals would greatly expand the species and numbers of wildlife that could be monitored for residual brodifacoum and other SGAR. The plasma elimination half-life of brodifacoum is shorter (days) than hepatic half-life (months) in mammals (e.g., Breckenridge et al. 1985), thus detection of residues in blood samples could provide more precise estimates of when exposure occurred. Trudeau et al. (2007) describe application of a small volume dried blood spot (DBS) sampling for monitoring pesticide exposure in birds. To further investigate develop this as a minimally

Proc. 24th Vertebr. Pest Conf. (R. M. Timm and K. A. Fagerstone, Eds.)  
Published at Univ. of Calif., Davis. 2010.  
Pg. 167-171.
invasive sampling procedure detecting sublethal brodifacoum exposure in live birds, a method for detecting brodifacoum in DBS samples from chickens (*Gallus gallus*) was validated using HPLC. In a second trial, chickens were orally administered a single sublethal dose of brodifacoum and residual brodifacoum concentrations were measured in DBS and plasma samples taken over the following 14 days.

### METHODS

#### Validation of Dried Blood Spot Method for Detecting Brodifacoum

Seven 21-day-old Ross male broiler chickens were kept on sawdust litter on a concrete floor in a pen. A 0.5% stock solution of brodifacoum in ethanol was diluted 1:9 with water, and orally administered to chickens to deliver a dose of 1 mg/kg bodyweight. Blood was sampled from the right jugular vein at Days 1 (*n* = 3), 3 (*n* = 3), and 7 (*n* = 1) after dosing, with approximately 3 mL taken via a 21-gauge needle into a Vacutainer tube containing lithium heparin. The protocol described by Mei et al. (2001) was used for preparation of DBS samples. Aliquots (50 µL) of fresh blood were placed onto the marked ‘wells’ on Schleicher and Schuell No. 903 filter paper cards (Whatman International Ltd., Maidstone, Kent, UK). These were dried in a slide rack at room temperature for approximately 2 h, wrapped in weighing paper, and placed in water impermeable plastic bags with 1-g silica gel desiccant packages and humidity-indicating paper. The sealed bags were stored at -20°C for approximately 5 months before analysis. At analysis, the 50-µL spots were cut from each card, folded, and placed in 20-mL screw-cap tubes. Three milliliters of methanol/water/acetic acid, and passed through a 0.45-µm syringe filter for HPLC analysis. The extract was transferred to a clean 10-mL test tube and gently evaporated at 50°C under air. The solvent was again gently evaporated at 50°C under air, the sample dissolved in a mobile phase of methanol/water/acetic acid, and passed through a 0.45-µm syringe filter for HPLC analysis. Aliquots were chromatographed on an Alltech® Alltima™ C18 column (Alltech Associates, Deerfield, IL) using methanol/water/acetic acid as the mobile phase. The post-column reagent was ammonia/methanol/water (10/10/80), with a flow rate adjusted until the effluent had a pH of approximately 10.1. The HPLC was run at a flow rate of 1.5 mL/min with degassing, with the gradient program: initial 65%A; 5%B; 8 minutes 84%A; 16%B; 16 minutes 95%A; 5%B; 20 minutes 95%A; 5%B; 23 minutes 65%A; 35%B. The fluorescence detector was set at 310-nm excitation and 390-nm emission. Samples spiked with 1, 5, or 10 µL of brodifacoum in methanol were also analysed.

### Comparison of Brodifacoum in DBS and Plasma Samples

A dose of 0.5 mg/kg brodifacoum was selected to represent a low sublethal exposure, based on known brodifacoum toxicity in chickens and other birds: Lund (1981) reported that brodifacoum killed 4 leghorn hens in 6-12 days after an average intake of 10.5 mg/kg, an LD₅₀ estimate of 3.3 (95% CI 2.2-5.2) mg/kg in quail (*Callipepla californica*) (Godfrey 1985), and a report by Bailey et al. (2005) of 100% mortality in 10 chickens gavage-dosed with 3 mg/kg brodifacoum. Twenty ‘Isabrown’ pullets were given a numbered leg band and acclimatised for 3 weeks to group-housing in large outdoor grassed pens with sheltered roosts with fresh water and commercial pellet food freely available. After weighing, the chickens were randomly allocated to either ‘sublethal brodifacoum’ (*n* = 15) or ‘control’ (*n* = 5) treatments. A dosing solution of 0.4 mg/mL brodifacoum in monopropylene glycol (MPG) was administered by stomach tube to hens in the brodifacoum treatment at 1.25 mL solution per kg of bodyweight. Control hens were administered 1.25 mL/kg of MPG alone, with a 2.5 mL maximum dose volume in either treatment. After dosing, the hens were placed back in group housing outdoors. Hens were sampled in groups of 5 (*n* = 4 brodifacoum-dosed and 1 control hen) on Days 1, 4, 7, and 14 after dosing. One hen was mistakenly dosed with control treatment, so the Day 14 sample included only 3 brodifacoum-dosed hens. At each sample day, DBS samples were taken first, where hens were restrained on their side, with the legs and upper wing held and the lower wing extended outwards to expose the brachial vein. The feathers underneath the wing were swabbed with disinfectant and held to one side, while a second person drew blood (maximum 0.2 mL) from the brachial vein with a 25 G needle. Single drops of blood were immediately placed directly from the syringe onto the 3 marked ‘wells’ on Schleicher and Schuell No. 903 filter paper cards. The DBS cards were dried in a slide rack at room temperature for approximately 2 h, then placed in ziplock plastic bags. Immediately after DBS sampling, the hens were euthanased by decapitation, and whole blood was collected directly into two 4,5-mL tubes (Vacutainer® blood collection tubes, 3.8% sodium citrate). Within an hour of sampling, whole blood was centrifuged at 2500 × g for 15 min at 4°C, with plasma divided into 2 Eppendorf tubes and frozen at -80°C. Analysis of plasma samples for brodifacoum was based on methods described by Primus et al. (2001) and Jones (1996). Plasma was thawed in a hot water bath at 37°C and 1 mL extracted with acetonitrile to remove protein. Ethyl ether was added to remove water and the sample evaporated on a vacuum evaporator. The residue taken up in methanol was analysed by HPLC, where fluorescence detection and a post-column pH switching technique was used to exploit the natural fluorescence of brodifacoum, with difenacoum as an internal standard.

### RESULTS

#### Validation of Dried Blood Spot Method for Detecting Brodifacoum

The MDL for brodifacoum in DBS was 0.04 ppm, spike recovery ranged from 87 to 122%, and the method uncertainty (95% CI) was ±4%. At Day 1 after dosing, residual brodifacoum in DBS samples were 0.375, 0.411, and 0.411 ppm; at Day 3 after dosing, 0.045, 0.051, and 0.051 ppm.
0.059 ppm, and at Day 7 after dosing 0.021 ppm.

**Comparison of Brodifacoum in DBS and Plasma Samples**

Spiked DBS samples had an 89-99% recovery and method uncertainty (95% CI) was ±10%, and spike recovery in plasma ranged from 88 to 100% with method uncertainty ±8%. Method detection limits were 0.04 ppm and 0.005 ppm for DBS and plasma samples, respectively. No brodifacoum was detected in any plasma or DBS samples from control hens. DBS samples taken at Day 1 after dosing with brodifacoum had a mean concentration of 0.144 ppm (± SE 0.036), and in plasma samples from the same day mean brodifacoum concentrations was 0.215 µg/mL (± SE 0.064). Plasma concentrations were below MDL by Day 7, and in DBS were nominally below MDL from Day 4 onwards (Table 1). The Spearman Rank Correlation Coefficient between detectable concentrations in DBS and corresponding plasma samples was 0.981.

**Table 1. Concentrations of residual brodifacoum detected in corresponding chicken plasma and DBS samples after oral administration of 0.5 mg/kg brodifacoum.** The analyzing laboratory noted that Day 4 DBS samples had repeatedly detectable concentrations of brodifacoum which were below the calculated MDL that are shown in brackets.

| Day | Chicken ID | Plasma [MDL 0.005] | DBS [MDL 0.04] |
|-----|------------|-------------------|----------------|
| 1   | #247       | 0.40              | 0.25           |
|     | #686       | 0.19              | 0.11           |
|     | #666       | 0.16              | 0.12           |
|     | #683       | 0.11              | 0.097          |
|     | #229 (control) | <MDL           | <MDL           |
| 4   | #695       | 0.012             | (0.010, 0.011) |
|     | #690       | 0.011             | (0.012, 0.011) |
|     | #681       | 0.014             | (0.016, 0.015) |
|     | #652       | 0.012             | (0.029, 0.020) |
|     | #693 (control) | <MDL           | (0.003, 0.002)* |
| 7   | #669       | <MDL              | <MDL           |
|     | #685       | <MDL              | <MDL           |
|     | #238       | <MDL              | <MDL           |
|     | #688       | <MDL              | <MDL           |
|     | #677 (control) | <MDL           | <MDL           |
| 14  | #218       | <MDL              | <MDL           |
|     | #653       | <MDL              | <MDL           |
|     | #700       | <MDL              | <MDL           |
|     | #205 (control) | <MDL           | <MDL           |

*Certainty on these below-MDL results could not be calculated.

**DISCUSSION**

The correlation between brodifacoum concentrations measured in DBS and plasma samples from hens at Day 1 indicates that DBS provided an accurate index of circulating brodifacoum concentrations within this timeframe. Coumarin anticoagulants bind to plasma albumin proteins (Sutcliffe et al. 1987), so dilution by non-binding fractions such as erythrocytes may have accounted for the generally lower brodifacoum concentrations measured in DBS (whole blood) in comparison to plasma samples, suggesting that a correction factor accounting for erythrocyte packed cell volume could be applied to DBS samples. Considering a normal packed cell volume of 32 for broiler chickens, the DBS values should be about one-third higher for a ‘plasma equivalent’. Plasma brodifacoum concentrations had fallen below MDL by Day 7, but in DBS were below MDL from Day 4 onwards (Table 1).

At 24 h after dosing with 0.5 mg/kg brodifacoum, chicken plasma concentrations in this trial were approximately 10 times higher than those measured by Howald (1997) in Japanese quail (Coturnix japonica) following sublethal exposure to brodifacoum. In his study, groups of 6 quail were dosed with 0.7, 1.4, or 0.35 mg/kg brodifacoum and plasma concentrations were not significantly different between the 3 dose groups 24 h later, with a mean of 0.028 ppm. In quail, plasma concentrations declined to a mean of 0.005 ppm at 5 days and then to 0.002 ppm by 10 days, showing a consistent rate of decline with the concentrations found here in chickens at 4 days (0.012-0.014 ppm) and 10 days (below 0.005 ppm MDL) after dosing. This suggests that, after sublethal exposure to brodifacoum, elimination of circulating (plasma bound) brodifacoum in birds occurs within approximately 7 days, representative of a “window of detectability” during which brodifacoum is at measurable concentrations in blood (plasma).

Although the plasma analysis was the more sensitive, it is probable that brodifacoum was also present in DBS samples at Day 4, as per the low but repeatable measurements noted by the reporting laboratory. It is also likely that improvements to the sensitivity of brodifacoum detection in DBS samples could be made. The utility of DBS as a minimally invasive monitoring technique could be improved by increasing the sensitivity of analyses for residual brodifacoum, potentially through more rigorous extraction or LC-MS detection. With currently established methods, using DBS over plasma samples is likely to slightly reduce the duration of detectability; however, we suggest that DBS has utility as a field monitoring tool for determining recent exposure to brodifacoum, especially where it is not desirable or possible to take sufficient blood to harvest a plasma sample, or to kill the animal to obtain liver tissue. Extending DBS sampling to also detect a range of second-generation anticoagulant rodenticides also fits well into a larger project to test birds for exposure to 6 groups of environmental contaminants (Shlosberg et al. 2009). A further reduction in invasiveness of monitoring for anticoagulant exposure may be possible using saliva samples. Sakai et al. (1983) found warfarin was excreted in the saliva of rabbits after oral administration; the salivary concentration corresponded with that in plasma and was correlated with the effect of warfarin on prothrombin complex activity. It would be useful to investigate whether coumarin anticoagulants occur in the saliva of sublethally-exposed birds in detectable concentrations comparable to those present in plasma and DBS.

In many countries, brodifacoum use is restricted to commensal rodent control (indoor) applications, yet predatory or scavenging wildlife species are being exposed, presumably through secondary environmental pathways of live rodent prey that have fed on bait, the carcasses of animals killed by brodifacoum, or invertebrates that have fed on bait and contain residual concentrations. Spurr et
al. (2005) provide recent evidence of commensal applications of anticoagulant bait resulting in transport of residues to a range of non-target wildlife in surrounding areas. Brakes and Smith (2005) demonstrate that routine commensal rat control using an anticoagulant reduced local populations of some non-target small mammals, demonstrating a significant route of secondary anticoagulant exposure for predators and scavengers. While the toxicological significance of apparently sublethal brodifacoum residues in wildlife remains uncertain (Kaukeinen et al. 2000), the potential for cumulative or chronic toxicosis needs further investigation. It may be that single or infrequent sublethal exposures do not significantly compromise long-term survival or reproductive fitness, but because the effects of cumulative or long-term exposure are not known, the ability to characterize field exposure profiles would be of great value in a proactive approach to identifying and minimizing risks to non-target wildlife. This is especially so, as the high toxicity and bioaccumulative potential of brodifacoum presents an additional concern where secondary exposure is likely to be repeated or sustained.

ACKNOWLEDGEMENTS

Initial DBS method development took place at the Kimron Veterinary Institute, Israel (2003) and was approved by the Animal Welfare Committee of the Veterinary Services. DBS analyses were carried out by Alan Shlosberg at Landcare Research, Lincoln, New Zealand in 2003. The second trial took place at Landcare Research, Lincoln, New Zealand in 2005 and was approved by the Landcare Research Animal Ethics Committee (Project 05/03/03) and funded by the Foundation for Science, Research and Technology (Contract C09X0209). Julie Turner, Ryan Moffat, and Susie Scobie provided technical assistance in maintaining and sampling the chickens.

LITERATURE CITED

ALBERT, C. A., L. K. WILSON, P. MINEAU, S. TRUDEAU, and J. E. ELLIOTT. 2009. Anticoagulant rodenticides in three owl species from western Canada, 1988-2003. Arch. Environ. Contam. Toxicol. 58(2): 451-459.

BAILEY, C., P. FISHER, and C. EASON. 2005. Assessing anticoagulant resistance in rats and coagulation effects in birds using small-volume blood samples. Science for Conservation 249, Department of Conservation, Wellington, N.Z.

BRAKES, C. R., and R. H. SMITH. 2005. Exposure of non-target small mammals to rodenticides: Short-term effects, recovery and implications for secondary poisoning. J. Appl. Ecol. 42:118-128.

BREXENRIDGE, A. M., S. CHOLERTON, J. A. HART, B. K. PARK, and A. K. SCOTT. 1985. A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. Brit. J. Pharmacol. 84:81-91.

DOWDING, C. V., R. F. SHORE, A. WORGAN, P. J. BAKER, and S. HARRIS. 2010. Accumulation of anticoagulant rodenticides in a non-target invertebrate, the European hedgehog (Erinaceus europaeus). Environ. Poll. 158:161-166.

EASON, C. T., G. R. WRIGHT, L. MEIKLE, and P. ELDER. 1996. The persistence and secondary poisoning risks of sodium monofluoroacetate (1080), brodifacoum, and cholecalciferol in possums. Proc. Vertebr. Pest Conf. 17:54-58.

FISHER, P., C. O’CONNOR, G. WRIGHT, and C. EASON. 2003. Persistence of four anticoagulant rodenticides in the liver of laboratory rats. DOC Science Internal Series 139, Department of Conservation, Wellington, N.Z.

GEBAUER, M. 2007. Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorganic Med. Chem. 15:2414-2420.

GODFREY, M. E. R. 1985. Non-target and secondary poisoning hazards of 'second generation' anticoagulants. Acta Zool. Fenn. 173:209-212.

HOARE, J. M., and K. M. HARE. 2006. The impact of brodifacoum on non-target wildlife: Gaps in knowledge. NZ J. Ecol. 30:157-167.

HOWALD, G. R. 1997. The risk of non-target species poisoning from brodifacoum used to eradicate rats from Langara Island, British Columbia. Masters thesis, Dept. of Animal Science, University of British Columbia, Vancouver, BC, Canada.

HOWALD, G., C. J. DONLAN, J. P. GALVAN, J. C. RUSSELL, J. PARKES, A. SAMANIEGO, Y. WANG, D. VEITICH, P. GENOVESI, M. PASCAL, A. SAUNDERS, and B. TERSHY. 2007. Invasive rodent eradication on islands. Conserv. Biol. 21:1258-1268.

JONES, A. 1996. HPLC determination of anticoagulant rodenticide residues in animal livers. Bull. Environ. Contam. Toxicol. 56:8-15.

KAUKEINEN, D. E., C. W. SPRAGINS, and J. F. HOBSON. 2000. Risk-benefit considerations in evaluating commensal anticoagulant rodenticide impacts to wildlife. Proc. Vertebr. Pest Conf. 19:245-256.

LAAS, F. Y., D. A. FORSS, and M. E. R. GODFREY. 1985. Retention of brodifacoum in sheep and excretion in faeces. NZ J. Agric. Res. 28:357-359.

LUND, M. 1981. Hens, eggs and anticoagulants. Int. Pest Contr. 23:126-128.

MEI, J. V., J. R. ALEXANDER, B. W. ADAM, and W. H. HANNON. 2001. Use of filter paper for the collection and analysis of human whole blood specimens. J. Nutr. 131:1631S-1636S.

MINEAU, P., P. A. MARTIN, L. K. WILSON, J. DUFFE, J. R. STEDELIN, and B. PUSCHNER. 2003. Extensive exposure of Canadian birds of prey to the second-generation anticoagulant rodenticides brodifacoum and bromadiolone. P. 312 in: Programme and Abstracts, 3rd Int. Wildlife Management Congress, 1-5 December 2003, Christchurch, NZ.

PELFRENE, A. F. 2001. Rodenticides. Pp. 1793-1836 in: R. Krieger (Ed.), Handbook of Pesticide Toxicology, Vol. 2. Academic Press, London.

PRIMUS, T. M., J. D. EISEMANN, G. H. MATSCHKE, C. RAMEY, and J. J. JOHNSTON. 2001. Chlorophacinone residues in rangeland rodents: An assessment of the potential risk of secondary toxicity to scavengers. Pp 164-180 in: J. J. Johnston (Ed.), Pesticides and Wildlife, ACS Symposium Series 771, American Chemical Society, Washington, DC.

SAKAI, K., A. NISHURA, Y. FUJHARA, T. KUTSANA, and T. NISHINO. 1983. Salivary excretion of warfarin in rabbits: Relationship between pharmacological effect and salivary pharmacokinetics of warfarin in rabbits. J. Pharmacobiodynamics 6:991-999.

SHLOSBERG, A., W. RUMBEHKA, K. KANNAN, A. LEHNER, O. HATZOFIE, T. GOUS, O. BONNEAHL, and O. CUNEAH.
2009. Monitoring of exposure to contaminants in two penguin species using dried blood spots in the DABSE Project. Pp. 4-5 in Session Abstracts, ‘Waterbirds as Indicators of Environmental Health’, 33rd Ann. Meeting of the Waterbird Society, Nov. 4-8, 2009, Cape May, NJ.

SHORE, R. F., J. D. S. BIRKS, A. AFSAAR, C. L. WIENBERG, and A. C. KITCHENER. 2003. Spatial and temporal analysis of second-generation anticoagulant rodenticide residues in polecats (Mustela putorius) from throughout their range in Britain, 1992-1999. Environ. Poll. 122:183-193.

SPURR, E. B., M. J. MAITLAND, G. E. TAYLOR, G. R. G. WRIGHT, C. D. RADFORD, and L. E. BROWN. 2005. Residues of brodifacoum and other anticoagulant pesticides in target and non-target species, Nelson Lakes National Park, New Zealand. NZ J. Zool. 32:237-249.

STONE, W. B., and J. C. OKONIEWSKI. 2003. Anticoagulant rodenticides and raptors: Recent findings from New York, 1998-2001. Bull. Environ. Contam. Toxicol. 70:34-40.

STUTCLIFFE, F. A., A. D. MACNICOLL, and G. C. GIBSON. 1987. Aspects of anticoagulant action: A review of the pharmacology, metabolism, and toxicology of warfarin and congeners. Rev. Drug Metab. Drug Interact. 5:226-261.

THIJSSEN, H. H. W. 1995. Warfarin-based rodenticides: mode of action and mechanism of resistance. Pesticide Sci. 43:73-78.

TRUDEAU, S., P. MINEAU, G. SANS CARTIER, G. FITZGERALD, L. WILSON, C. WHELER, and L. D. KNOPPER. 2007. Using dried blood spots stored on filter paper to measure cholinesterase activity in wild avian species. Biomarkers 12(2):145-154.